|Dr. RÃ©my Luthringer||Exec. Chairman & CEO||736.03k||N/A||1961|
|Mr. Geoffrey Robin Race||Exec. VP, CFO & Chief Bus. Officer||516.84k||N/A||1961|
|Mr. Joseph Reilly||Sr. VP & COO||N/A||N/A||1975|
|Mr. Frederick W. Ahlholm||Sr. VP & Chief Accounting Officer||N/A||N/A||1966|
|Mr. William B. Boni||VP of Investor Relations & Corp. Communications||N/A||N/A||1952|
|Mr. Devin Whittemore Smith||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||1968|
|Dr. Michael Davidson||Chief Medical Officer||N/A||N/A||1950|
|Dr. Jay B. Saoud Ph.D.||Sr. VP and Head of R&D||N/A||N/A||1959|
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Minerva Neurosciences, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 5.